Sernova Biotherapeutics (OTCMKTS:SEOVF – Get Free Report) posted its quarterly earnings data on Thursday. The company reported ($0.01) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.01), Zacks reports.
Sernova Biotherapeutics Stock Performance
Shares of OTCMKTS SEOVF traded up $0.00 during midday trading on Thursday, reaching $0.10. The company’s stock had a trading volume of 213,800 shares, compared to its average volume of 47,965. The company has a market cap of $38.52 million, a P/E ratio of -2.55 and a beta of 0.86. The business’s 50 day moving average price is $0.08 and its two-hundred day moving average price is $0.10. Sernova Biotherapeutics has a fifty-two week low of $0.07 and a fifty-two week high of $0.14.
About Sernova Biotherapeutics
Sernova Biotherapeutics is a clinical‐stage biotechnology company focused on developing and commercializing cell‐based therapeutic technologies for patients with chronic and life‐threatening diseases. Headquartered in London, Ontario, Canada, the firm is advancing an implantable device platform designed to support the long-term survival and function of therapeutic cells. The company’s lead product candidate, known as the Cell Pouch System, is engineered to create a vascularized environment in which transplanted cells can thrive, with an initial emphasis on treating patients with type 1 diabetes.
In its core program, Sernova has initiated a Phase I/II clinical trial evaluating the safety and efficacy of the Cell Pouch System in individuals with type 1 diabetes who require islet cell transplantation.
Further Reading
- Five stocks we like better than Sernova Biotherapeutics
- AeroVironment’s Record Backlog and Earnings Beat Fuel Recovery Case
- Corning Just Locked In a Massive Verizon Fiber Deal as AI Infrastructure Expands
- 3 Under-$20 Stocks Tied to the Future of U.S. Energy and Materials
- Uncle Sam’s Quantum Leap: Feds Fund a $300M Quantum Supercycle
Receive News & Ratings for Sernova Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sernova Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
